Tirzepatide dosage reference: typical range 2.5 – 15 mg, 1× per week, cycle Long-term; cycle off 4 weeks every 6 months. Titration chart, reconstitution…
Dual GLP-1/GIP agonist offering superior weight loss compared to semaglutide alone. The combination targets two incretin pathways for enhanced metabolic effects.
Published protocol literature for Tirzepatide describes a typical range of 2.5 – 15 mg, dosed 1× per week, over a cycle of Long-term; cycle off 4 weeks every 6 months. Reported half-life: approximately 5 days.
| Parameter | Reported value |
|---|---|
| Typical dose range | 2.5 – 15 mg |
| Frequency | 1× per week |
| Cycle length | Long-term; cycle off 4 weeks every 6 months |
| Half-life | Approximately 5 days |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | 5-Amino-1MQ (mitochondrial fat burn), CJC-1295 (recomp), Tesamorelin (visceral fat) |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how Tirzepatide dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 2.5 mg | Weekly | Start low; 4-week titration phases |
| Intermediate | 5–7.5 mg | Weekly | Accelerated fat loss begins |
| Advanced | 10–15 mg | Weekly | Maximum efficacy; hydrate well |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 2 mg vial | 1 mL bacteriostatic water | 2,000 mcg/mL |
| 5 mg vial | 2 mL bacteriostatic water | 2,500 mcg/mL |
| 10 mg vial | 2 mL bacteriostatic water | 5,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for Tirzepatide. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for Tirzepatide generally describes 2.5 – 15 mg, administered 1× per week. Individual protocols vary and should be set by a licensed practitioner.
1× per week. Frequency is driven by half-life — Tirzepatide has a reported half-life of approximately 5 days, so shorter-acting compounds are dosed more often.
Typical cycle length reported is Long-term; cycle off 4 weeks every 6 months. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
2mg → 1ml bacteriostatic water; 5mg → 2ml bacteriostatic water; 10mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
Head-to-head clinical trials (SURPASS-2) suggest greater average weight reduction with tirzepatide, but individual response varies and any clinical decision should be made with a licensed provider.
Tirzepatide activates two receptors (GIP and GLP-1) on the same molecule, in contrast to semaglutide which targets only GLP-1.